The 1,500 participants of the recent clinical trials of two vaccines to prevent the Ebola virus have since their inoculation reported no serious side effects, an official has disclosed. Dr. Mark Kieh, who is Site Physician of the Partnership for Research on Ebola Vaccines in Liberia (PREVAIL) at the Redemption Hospital in Monrovia, noted that the participants are being regularly monitored to determine the safety of the trial vaccine.
He told the Liberia News Agency recently that some of the side-effects that were reported, including fever, body pain and headache, were all minor effects. Kieh said the regular follow-up is part of PREVAIL’s Phase II mandate aimed at further authenticating the safety of the vaccine and at the same time determining whether one of the vaccines will prevent the Ebola disease.
He said, as expected, the clinical research is going on well, noting that cooperation from the participants remains a cardinal step in what the research has achieved so far.
The Liberia-U.S. Joint Clinical Research Partnership in February 2015 launched the clinical trials in Liberia of two vaccines, CAd3-ZEBOV and rVSV-ZEBOV, to find future protection against the Ebola virus. The vaccine study, termed the “Double-blind Randomized Placebo Trial”, saw the inoculation of 1,500 participants at the Redemption Hospital on Bushrod Island in Monrovia.